echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical trial application of Haisco's innovative drug HSK31858 tablets was accepted by the State Food and Drug Administration

    The clinical trial application of Haisco's innovative drug HSK31858 tablets was accepted by the State Food and Drug Administration

    • Last Update: 2022-01-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 29, Haisco issued an announcement stating that the company had recently received the "Notice of Acceptance" for HSK31868 tablets issued by the National Medical Products Administration


    HSK31858 tablets are an oral, potent and highly selective Dipeptidyl Peptidase 1 (DPP1) small molecule inhibitor independently developed by the company.


    The prevalence of bronchiectasis increases with age.


    After inquiries, the world’s fastest-growing co-target compound INS1007 is currently undergoing phase III clinical trials, and its phase II trial results show that it has a definite effect on bronchiectasis.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.